This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/053560-2025">https://www.find-tender.service.gov.uk/Notice/053560-2025</a>

Contract

# ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL

Northern Health And Social Care Trust

UK7: Contract details notice - Procurement Act 2023 - view information about notice types

Notice identifier: 2025/S 000-053560

Procurement identifier (OCID): ocds-h6vhtk-058761 (view related notices)

Published 3 September 2025, 2:09pm

### Scope

#### Reference

DAC134/0825PM

## **Description**

The intended contract is for the supply of Enhertu (Trastuzumab Deruxtecan) 100mg powder for solution for infusion to Northern Health and Social Care Trust for the period of three years

# Contract 1. ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL

## **Supplier**

ALLOGA UK LIMITED

#### **Contract value**

- £700,000 excluding VAT
- £840,000 including VAT

Above the relevant threshold

## **Date signed**

1 September 2025

#### **Contract dates**

- 1 September 2025 to 31 August 2028
- 3 years

#### Main procurement category

Goods

#### **CPV** classifications

• 33600000 - Pharmaceutical products

<b>^</b> -		_ 4	locations
	ntra	CT	INCATIONS
vu	1111 a	GL I	iocalions

• UKN - Northern Ireland

## Justification for not setting key performance indicators

Not applicable as contract value is less than £5 million

#### Other information

#### Conflicts assessment prepared/revised

Yes

#### **Procedure**

## **Procedure type**

Direct award

## **Direct award justification**

Single supplier - technical reasons

Purchase of drugs which are subject to patent protection/ Sole MA Holder, where no reasonable alternative or substitute exists.

Section 41 schedule 5(5) of the PA2023 permits a direct award in the case of single supplier and permits the award if the following conditions are met in relations to the public contract -

(a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and

(b)there are no reasonable alternatives to those goods, services or works.

The Northern Health and Social Care Trust requires the purchase of enhertu which is subject to patent protection.

These essential medicines are required from this supplier to ensure continuity of patient care.

The absence of competition is not the artificial narrowing of the parameters of the procurement.

# **Supplier**

#### **ALLOGA UK LIMITED**

• Companies House: 03169255

Public Procurement Organisation Number: PBTH-6754-GVPN

**Amber Park** 

Alfreton

DE55 2FH

**United Kingdom** 

Email: allogauk.enquiries@alloga.co.uk

Website: <a href="https://www.alloga.co.uk/">https://www.alloga.co.uk/</a>

Region: UKF12 - East Derbyshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 1. ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL

## **Contracting authority**

#### **Northern Health And Social Care Trust**

Public Procurement Organisation Number: PBRP-6676-CQZY

Brettan Hall, Antrim Area Hospital, Bush Road

Antrim

**BT41 2RL** 

**United Kingdom** 

Email: diane.trimble@northerntrust.hscni.net

Region: UKN0D - Antrim and Newtownabbey

Organisation type: Public authority - central government

Devolved regulations that apply: Northern Ireland